文献速递神经头颈PETMR

动态68Ga-DOTATATE PET/MRI在颅内脑膜瘤诊断与管理中的应用

Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas.
PubMed 文献 · Radiol Imaging Cancer · 2022-01-01

这项前瞻性研究(DOMINO-START,NCT04081701)在19例脑膜瘤患者中评估动态68Ga-DOTATATE脑PET/MRI的多参数SUV与Patlak净结合速率常数Ki成像,并优化静态采集时间窗。结果显示最大SUV50与Patlak Ki强正相关(r=0.82–0.85),Ki图像可提高病灶对比度,SUV10平均评分高于SUV50(P<.001)。

要点

  • 最大SUV50与Patlak Ki强正相关(绝对r=0.82,相对r=0.85;均P<.001)。
  • Patlak Ki图像通过抑制非特异性背景信号提高病灶对比度。
  • 脑膜瘤组SUV10平均评分高于SUV50(P<.001),提示可优化注射后静态采集窗。

核心结论

  • 联合SUV与Patlak Ki的68Ga-DOTATATE PET/MRI可实现脑膜瘤多参数评估,Ki成像有潜力提高病灶对比度,并优化SUV测量在注射后的时间窗。

研究设计与样本

  • 前瞻性研究(DOMINO-START,NCT04081701),19例脑膜瘤参与者(平均年龄63岁,范围36–89岁,13例女性,2019–2021年),共84个感兴趣体积;Patlak分析采用基于独立数据集9例参与者构建的、经验证的群体参考组织时间-活性曲线模型。

关键影像表现/征象

  • Patlak Ki图像通过抑制非特异性背景信号产生更高的病灶对比度。
  • 绝对与相对最大SUV50均与脑膜瘤Patlak Ki呈强正相关(分别为r=0.82,P<.001;r=0.85,P<.001)。
  • 治疗后改变病灶中绝对与相对最大SUV50亦与Patlak Ki强正相关(分别为r=0.88,P=.007;r=0.83,P=.02)。

诊断标准与关键数值

  • 所有SUV50与SUV10指标在脑膜瘤与治疗后改变区域之间差异均有统计学意义(P<.001)。
  • 脑膜瘤组内SUV10平均评分高于SUV50(P<.001)。
  • SUV与Ki相关性采用Spearman相关分析;SUV50与SUV10比较采用Wilcoxon配对符号秩检验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate dynamic gallium 68 (68Ga) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) brain PET/MRI as an adjunct modality in meningioma, enabling multiparametric standardized uptake value (SUV) and Patlak net binding rate constant (Ki) imaging, and to optimize static acquisition period. Materials and Methods In this prospective study (ClinicalTrials.gov no. NCT04081701, DOMINO-START), 68Ga-DOTATATE PET/MRI-derived time-activity curves (TACs) were measured in 84 volumes of interest in 19 participants (mean age, 63 years; range, 36-89 years; 13 women; 2019-2021) with meningiomas. Region- and voxel-specific Ki were determined using Patlak analysis with a validated population-based reference tissue TAC model built from an independent data set of nine participants. Mean and maximum absolute and relative-to-superior-sagittal-sinus SUVs were extracted from the entire 50 minutes (SUV50) and last 10 minutes (SUV10) of acquisition. SUV versus Ki Spearman correlation, SUV and Ki meningioma versus posttreatment-change Mann-Whitney U tests, and SUV50 versus SUV10 Wilcoxon matched-pairs signed rank tests were performed. Results Absolute and relative maximum SUV50 demonstrated a strong positive correlation with Patlak Ki in meningioma (r = 0.82, P < .001 and r = 0.85, P < .001, respectively) and posttreatment-change lesions (r = 0.88, P = .007 and r = 0.83, P = .02, respectively). Patlak Ki images yielded higher lesion contrast by mitigating nonspecific background signal. All SUV50 and SUV10 metrics differed between meningioma and posttreatment-change regions (P < .001). Within the meningioma group, SUV10 attained higher mean scores than SUV50 (P < .001). Conclusion Combined SUV and Patlak Ki68Ga-DOTATATE PET/MRI enabled multiparametric evaluation of meningioma, offering the potential to enhance lesion contrast with Ki imaging and optimize the SUV measurement postinjection window. Keywords: Molecular Imaging-Clinical Translation, Neuro-Oncology, PET/MRI, Dynamic, Patlak ClinicalTrials.gov registration no. NCT04081701 © RSNA, 2022.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Ivanidze J, Roytman M, Skafida M, et al. Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas. Radiol Imaging Cancer. 2022. PMID: 35275019. doi:10.1148/rycan.210067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。